As the first company to file an application to produce a Gleevec generic in the US, Mumbai-based Sun Pharmaceutical Industries Ltd. gained six months of marketing exclusivity – which ended this month.
Now two generic competitors have entered the market with their own versions and more are expected. This will add to pricing pressure on the drug that Swiss giant Novartis...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?